Skip to Content

Rubraca (rucaparib) Disease Interactions

There are 3 disease interactions with Rubraca (rucaparib):

Moderate

Rucaparib (Includes Rubraca) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Based on population pharmacokinetic analyses no dose adjustment is recommended for patients with mild hepatic impairment. Caution should be exercised when using this agent in patients with moderate to severe hepatic impairment as the pharmacokinetics of rucaparib in these patients are unknown.

Moderate

Rucaparib (Includes Rubraca) ↔ Mds/Aml

Moderate Potential Hazard, Moderate plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

Cases of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) have been reported with the use of rucaparib. It is recommended to monitor complete blood count at baseline and monthly thereafter, and as clinically appropriate. Do not start rucaparib until patients have recovered from hematological toxicity caused by previous chemotherapy. It might be necessary to interrupt therapy with rucaparib until blood counts have recovered. If MDS/AML is confirmed, rucaparib should be discontinued.

Moderate

Rucaparib (Includes Rubraca) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

No dose adjustment is recommended for patients with mild to moderate renal impairment. Caution should be exercised when using this agent in patients with severe renal impairment or patients on dialysis as the pharmacokinetics of rucaparib in these patients are unknown.

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide